英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Endo - Home | Introducing Keenova and Par Health
    On July 31, 2025, Mallinckrodt and Endo joined together to better serve patients and customers with a bold plan for the future Following the merger, the combined company then spun off its generics and sterile injectables business as an independent company—Par Health—and rebranded the specialty therapeutics company as Keenova Therapeutics in November 2025
  • Investors | Endo - Press Releases
    Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader - Highly Complementary Companies to Advance Therapies to Address Unmet Patient Needs - Respective Generics Businesses and Endo's Sterile Injectables Business to be Combined and Spun Off as an Independent Company with Target Date in the Fourth Quarter of
  • Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company
    Mallinckrodt and Endo commenced mailing of the definitive joint proxy statement prospectus to shareholders of Mallinckrodt and Endo, respectively, on or about May 12, 2025
  • Mallinckrodt and Endo to Combine to Create a Global, Scaled . . .
    About Endo Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies Our passionate team members collaborate to develop and deliver these essential medicines Together, we are committed to helping everyone we serve live their best life Learn more at www endo com or connect with us on LinkedIn
  • Endo Reports Fourth-Quarter and Full-Year 2024 Financial Results
    Endo achieved 2024 revenues and adjusted EBITDA expectations, while progressing the Company's strategic priorities XIAFLEX® hit record revenues of $516 million in 2024, up 9% versus 2023 The Company provides 2025 revenue guidance of $1,775 to $1,860 million and adjusted EBITDA guidance of $620 to $650 million MALVERN, Pa , March 13, 2025 PRNewswire -- Endo, Inc ("Endo" or the "Company
  • Investors | Endo - Overview
    Endo’s board of directors oversees and advises our leaders to protect the long-term interests of the company and our shareholders The experienced and independent board members are committed to building sustainable success
  • Endo, Inc. Completes Acquisition of Endo International plcs Assets
    MALVERN, Pa , April 23, 2024 PRNewswire -- Endo, Inc ("Endo" or the "Company"), a newly formed entity, today announced that it has successfully completed the previously announced acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization (the "Plan")
  • Endo Receives U. S. FDA Approval of Manufacturing Facility in Indore . . .
    20,000-square-foot site increases Endo's sterile injectable production capacity This marks the site's first U S FDA approval Endo is investing and innovating in its Injectable Solutions business MALVERN, Pa , Dec 9, 2024 PRNewswire -- Endo, Inc (OTCQX: NDOI) announced today that the U S Food and Drug Administration (FDA) has approved commercial production of VASOSTRICT ® (vasopressin
  • Financial Information - Endo International plc
    Combining with Mallinckrodt MNK-Endo Transaction Release MNK-Endo Transaction Presentation Webcast Form of Voting Agreement MNK-Endo Transaction Progress
  • Mallinckrodt and Endo Announce Significant Progress in Proposed Merger
    As announced on March 13, 2025, the proposed Mallinckrodt and Endo transaction envisions the spin-off of the combined generic pharmaceuticals businesses and Endo's sterile injectables business into a new standalone entity separate from the remaining branded pharmaceuticals business





中文字典-英文字典  2005-2009